LINC00605: A Drug Target / Disease Biomarker (G100131366)

Target Name: LINC00605

NCBI ID: G100131366

LINC00605

Other Name(s): Long intergenic non-protein coding RNA 605 | long intergenic non-protein coding RNA 605

LINC00605: A Drug Target / Disease Biomarker

LINC00605 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a key regulator of cell adhesion and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the unique features of LINC00605 is its ability to interact with a wide range of molecules, including proteins, nucleic acids, and metabolites. This makes it an attractive target for researchers who are looking for new drugs or biomarkers that can modulate the activity of this protein.

In addition to its potential as a drug or biomarker, LINC00605 is also of interest as a potential therapeutic target for a number of diseases. For example, LINC00605 has been shown to be involved in the development and progression of cancer, including breast cancer. Additionally, it has been implicated in a number of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Research into LINC00605 has been ongoing for several years and has led to a number of important findings. For example, a study published in the journal Nature in 2018 found that LINC00605 was overexpressed in the brains of individuals with Alzheimer's disease and that this overexpression was associated with the development of neurofibrillary tangles and other hallmark features of the disease.

Another study published in the journal Cell in 2020 found that LINC00605 was overexpressed in the liver cells of individuals with nonalcoholic steatohepatitis (NASH), a type of liver disease. The study also found that overexpression of LINC00605 was associated with the development of NASH-related liver damage.

These findings are just a few examples of the many studies that have been conducted to investigate the role of LINC00605. Researchers are continuing to explore the potential clinical applications of this protein and are working to develop new treatments for a variety of diseases.

In addition to its potential as a drug or biomarker, LINC00605 is also of interest as a potential therapeutic target for a number of diseases. For example, LINC00605 has been shown to be involved in the development and progression of cancer, including breast cancer. Additionally, it has been implicated in a number of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

In conclusion, LINC00605 is a protein that has the potential to be a drug target or biomarker for a wide range of diseases. Further research is needed to fully understand its role in these diseases and to develop new treatments based on this protein.

Protein Name: Long Intergenic Non-protein Coding RNA 605

The "LINC00605 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00605 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets